News

8
Nov

PRESS RELEASE – Dr. Nicolas Gaudenzio is appointed Chief Scientific Officer at Genoskin

Genoskin appoints Dr Nicolas Gaudenzio as Chief Scientific Officer Today, November 8, Genoskin announces the appointment of Dr. Nicolas Gaudenzio as Chief Scientific Officer (CSO), starting in November. Dr. Gaudenzio will lead Genoskin's shift towards new activities Dr. Gaudenzio is a world-renowned researcher and expert in immunology and allergic skin inflammation. He is also principal investigator and leader of a
Read more
9
Jun

Interview with Pr. Guy Serre

10 Year Anniversary: Interview with Pr. Guy Serre For our 10th anniversary, we spoke to people who helped Genoskin become what it is today. Back in March, we had a chat with Pr. Guy Serre, Director of the UDEAR lab (Epidermis Differentiation and Rheumatoid Autoimmunity Unit), the place where Genoskin was born. Genoskin: Could you describe the relationship between your
Read more
28
Oct

A unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin

The FlowSkin® platform : a unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin When human tissue culture meets microfluidic technology, it leads to the first perfused human skin model ; an amazing platform to overcome the challenges of drug development and replace animal testing. Almost 10 years ago now, Genoskin developed the
Read more
7
Oct

Genoskin answers questions from National Anti-Vivisection Society

Genoskin interviewed by the National Anti-Vivisection Society on alternatives to animal testing Genoskin’s Chief Commercial Officer, Eric Merle, recently had the opportunity to speak with the National Anti-Vivisection Society (NAVS). Through a Q&A, Eric explains why Genoskin’s ex vivo human skin assays are a reliable alternative to animal testing. “We generate human data” Even though testing new drugs and compounds
Read more
2
Oct

Genoskin & LEO Pharma publish data on inflammation model InflammaSkin® in Experimental Dermatology

Genoskin & LEO Pharma publish data on inflammation model InflammaSkin® in Experimental Dermatology Genoskin’s amazing team of experts is always developing new and improved ex vivo human skin assays. This time, we partnered with LEO Pharma to develop a brand new inflammation model: InflammaSkin®. Genoskin is proud to announce that its unique skin assay is now fully described in Experimental
Read more
30
Sep

Pharma’s Almanac: Overcoming skin assays challenges with living human skin models

Pharma's Almanac: Overcoming skin assays challenges with living human skin models Genoskin’s CEO, Pascal Descargues was asked to contribute to the next issue of Pharma’s Almanac. It’s increasingly critical for pharmaceutical companies to develop drugs faster and more efficiently. In this article, Pascal gives some insights into how living human skin models help accelerate research.  For decades, the norm for
Read more